Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577851 | 1.00 | L3MBTL1 (0.49) | L3MBTL1IDO1CA12CA1CA2 | |
| SCHEMBL20696473 | 0.84 | CA12 (0.44) | CA12CA1CA2CA9RIPK1 | |
| SCHEMBL6805430 | 0.84 | L3MBTL1 (0.57) | L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL29049638 | 0.83 | GABRA1 (0.45) | L3MBTL1IDO1CA12CA1CA2 | |
| SCHEMBL1449282 | 0.82 | CA12 (0.47) | IDO1CA12CA1CA2CA9 | |
| SCHEMBL1778391 | 0.82 | CA12 (0.47) | IDO1CA12CA1CA2CA9 | |
| SCHEMBL4685384 | 0.82 | TAAR1 (0.47) | IDO1CA12CA1CA2CA9 | |
| Benzene SCHEMBL10992898 | 0.81 | L3MBTL1 (0.60) | L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL29993025 | 0.80 | L3MBTL1 (0.40) | L3MBTL1IDO1CA12CA1CA2 | |
| SCHEMBL286410 | 0.80 | AKR1B1 (0.61) | CA12CA1CA2CA9GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490668-B | Pyrimidylimidazole compound, preparation method thereof and organic solderability preservative | 深圳市贝加电子材料有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-110041282-B | Parecoxib sodium related substance, preparation method and application thereof | 正大天晴药业集团股份有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-114015342-A | Antistatic scratch-resistant automobile paint and preparation method thereof | 黄超财 | 2022-02-08 | — | — | CN | claimed |
| CN-108863740-B | Preparation method of naphthalenone compound | 南昌航空大学 | 2021-04-02 | — | — | CN | claimed |
| CN-104710256-A | Cheap and efficient synthesis method of alpha-hydroxyketone compound | UNIV BEIJING | 2015-06-17 | — | — | CN | claimed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-119638663-A | Flavone derivative and microwave preparation method and application thereof | 延边大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119409562-A | Preparation method of alpha-bromo aromatic ketone compound | 丽水学院 | 2025-02-11 | — | — | CN | disclosed |
| CN-115975968-B | Amine dehydrogenase mutant and application thereof in chiral amine synthesis | 中国科学院天津工业生物技术研究所 | 2024-08-02 | — | — | CN | disclosed |
| CN-115490668-B | Pyrimidylimidazole compound, preparation method thereof and organic solderability preservative | 深圳市贝加电子材料有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| EP-0626068-A1 | LUMINESCENT LANTHANIDE CHELATES | WALLAC OY (FI) | 1994-11-30 | — | — | EP | disclosed |
| US-4960798-A | Methods for the treatment of angina | MCNEILAB, INC. (US) | 1990-10-02 | — | — | US | disclosed |
| US-4898889-A | Methods for the treatment of hypertension | MCNEILAB, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4742084-A | Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives | MCNEILAB, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4661635-A | ANTIARRHYTHMIA AGENTS | MCNEILAB, INC. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0146271-A2 | Aralykyl (arylethynyl) aralkyl amines for use as vasodilators and antihypertensives | McNeilab, Inc. (US) | 1985-06-26 | — | — | EP | disclosed |
| EP-0145361-A2 | Acetylene derivatives for the treatment of hypertension and angina | McNeilab, Inc. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | L3MBTL1 3825/4885IDO1 4527/4885CA12 3290/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | L3MBTL1 3825/4885IDO1 4527/4885CA12 3290/4885 |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | POLRMT, TFAM, UQCRC1 | L3MBTL1 1024/4885IDO1 2113/4885CA12 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.